Acute promyelocytic leukemia after mitoxantrone therapy for multiple sclerosis.

@article{Ramkumar2008AcutePL,
  title={Acute promyelocytic leukemia after mitoxantrone therapy for multiple sclerosis.},
  author={Bhuvaneswari Ramkumar and Manpreet Kaur Chadha and Maurice Barcos and Sheila N. J. Sait and Meyer R Heyman and Maria R. Baer},
  journal={Cancer genetics and cytogenetics},
  year={2008},
  volume={182 2},
  pages={126-9}
}
Mitoxantrone is a DNA-topoisomerase 2 inhibitor used as a single agent for treatment of relapsing-remitting or progressive multiple sclerosis (MS). We present here two patients treated with mitoxantrone for MS who subsequently developed acute promyelocytic leukemia (APL). These constitute, to our knowledge, the eighth and ninth reports of APL in patients treated with mitoxantrone for MS. Topoisomerase 2 inhibitors are associated with therapy-related acute myeloid leukemia (t-AML) with 11q23… CONTINUE READING